The company posts PAT at Rs 156 crore, up 30.3 per cent YoY

Emcure Pharmaceuticals announced its unaudited consolidated financial results for the quarter ended December 31st, 2024.

The quarter saw strong growth led by international businesses that grew 23 per cent YoY. The Canadian business continues to perform well, achieving a 34 per cent YoY growth and the Mantra subsidiary is now fully integrated. The company’s Rest of the World (RoW) market business grew a robust 40 per cent YoY aided by strong growth in our non-ARV segment. The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12 per cent to Rs 888 crore, led by a steady performance in the base business and aided by in-licensed products.

Satish Mehta, CEO and MD, Emcure Pharmaceuticals, said, “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on the back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”

· Revenue from operations at Rs 1,963 crore, up 17.7 per cent YoY
· EBITDA margins at 18.4 per cent with EBITDA up 23.2 per cent YoY
· PAT at Rs 156 crore, up 30.3 per cent YoY
· Domestic business sales at 888 crore, up 12 per cent YoY
· International business sales at 1,075 crore, up 23 per cent YoY